Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1065890?
NBI-1065890 is commercialized by Neurocrine Biosciences, with a leading Phase I program in Psychiatric Disorders. According to Globaldata, it is...
Data Insights
NBI-1065890 by Neurocrine Biosciences for Psychiatric Disorders: Likelihood of Approval
NBI-1065890 is under clinical development by Neurocrine Biosciences and currently in Phase I for Psychiatric Disorders. According to GlobalData, Phase...